PURPOSE:
To facilitate reduction of morbidity and mortality associated with opioid overdose by increasing access and distribution of Naloxone Hydrochloride (Narcan®) to persons at risk of experiencing or witnessing an opioid overdose, pursuant to RCW 69.41.095.

INDICATIONS:
Naloxone is indicated for treatment of opioid overdose. It may be delivered intramuscularly with a syringe and vial, or Evzio auto-injector or intra-nasally with the use of a mucosal atomizer device.

Naloxone may be distributed to clients, family, friends and peers of clients, and professionals at Clark County Public Health’s (CCPH) Syringe Exchange (SE). Naloxone is also made available to appropriate CCPH staff and community agencies who serve clients who use opiates or at risk of opiate use.

This standing order authorizes CCPH Syringe Services Program (SSP) staffs that have successfully completed naloxone training, to possess and distribute naloxone kits to participants of the Overdose Prevention Program who have successfully completed overdose training for the purpose of reducing opioid-related overdose deaths.

Overdose Prevention Program participants must meet all of the following criteria:
- Current opioid users, individuals with a history of opioid use, or someone with frequent contact with opioid users;
- Risk for overdose or likelihood of contact with someone at risk, by report or history;
- Demonstrated ability to understand and willingness to learn the essential components of Overdose Prevention and Response and naloxone administration.

The educational program components will include:
- Overdose prevention techniques
- Recognizing signs and symptoms of overdose
- Calling 911
- Airway and breathing assessment
- Rescue breathing and/or chest compressions
- Naloxone storage, carrying, and administration
- Post-overdose follow-up and care

Upon completion of the educational component, the participant will be assessed by the CCPH SSP trainer on their understanding of the information and their comfort with the basic components of overdose response. Naloxone will be dispensed to trained program participants who successfully complete the outlined overdose prevention training and demonstrate willingness to carry and use naloxone to treat individuals experiencing an opioid overdose.

Order to Distribute:
Upon participant completion of CCPH Overdose Prevention and Response training distribute for use by a trained program participant one of the kits outlined below:
- Injection kit
• Evzio<sup>4</sup> auto-injection kit
• Intra-nasal kit<sup>5</sup>

Naloxone Kit contents:

### Injection Kit<sup>5</sup>:
- Two 1cc vials naloxone hydrochloride (concentration 0.4mg/ml)
- Two 3ml syringes with 22g 1 1/2" needles
- 2 Alcohol Pads
- Two pair of gloves
- Rescue breathing mask
- Overdose prevention tips & instructions to use Naloxone

### Intra-nasal Kit<sup>5</sup>:
- Two 1cc vials naloxone hydrochloride (concentration 0.4mg/ml) nasal spray
- Two pair of gloves
- Rescue breathing mask
- Overdose prevention tips & instructions to use Naloxone

### Evzio<sup>4</sup> Auto-Injection Kit:
- One trainer device
- Two 2 mg naloxone hydrochloride injectors
- 2 Alcohol Pads
- Two pair of gloves
- Rescue breathing mask
- Overdose prevention tips & instructions to use Naloxone

Naloxone Security & Storage:
Syringe exchange staff shall ensure that naloxone kits are securely stored under conditions consistent with the manufacturer’s guidelines.

Refills:
- Qualified Overdose Responders will be eligible to receive take-home naloxone refills upon completion of a follow-up assessment.
- Overdose Prevention Educators will document the refill information in the naloxone database per the database guidelines.

**DOCUMENTATION:**
- CCPH SSP training staff will document eligible participant training completion in the CCPH naloxone database per program guidelines.
- Naloxone dispensing will be documented per program guidelines outlined in the naloxone database guide.

**INVENTORY MANAGEMENT:**
Refer to SSP operations toolkit for inventory guidelines.

**CRITERIA FOR NOTIFYING HEALTH OFFICER:**
- Immediately in the event of an adverse reaction or unexpected symptoms, complications or other situations occur following medication administration.

**DEFINITION OF TERMS:**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCPH</td>
<td>Clark County Public Health</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>NIDA</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>PCP</td>
<td>Primary care provider</td>
</tr>
<tr>
<td>PHN</td>
<td>Public Health Nurse</td>
</tr>
<tr>
<td>SE</td>
<td>Syringe exchange</td>
</tr>
<tr>
<td>SO</td>
<td>standing order</td>
</tr>
</tbody>
</table>
REFERENCES:
1. WA State Law. Opioid overdose medication. RCW 69.41.095 Opioid overdose medication
2. WA State Law. RCW 69.50.315
4. Evzio https://evzio.com/patient
5. National Institute on Drug Abuse (NIDA), Opioid Overdose Reversal with Naloxone (Narcan, Evzio)
   https://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxone-narcan-evzio

LEGAL AUTHORITY:
- Opioid overdose medication. RCW 69.41.095 Opioid overdose medication
- Medical assistance—Drug-related overdose—Prosecution for possession. RCW 69.50.315

REVISION HISTORY:

<table>
<thead>
<tr>
<th>Revised:</th>
<th>By:</th>
<th>Summary of Revisions Made:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2015</td>
<td>Pam Dykes</td>
<td>Replaced &quot;dispense&quot; with &quot;distribute&quot; in the document. Added that training is provided to community members on page 1 and that naloxone kits are securely stored under conditions consistent with the manufacture’s guidelines (and removed at the harm reduction center – in case we ever keep a supply at CCPH). I changed the review period of the protocol to every 2 years instead of one.</td>
</tr>
<tr>
<td>4/23/19</td>
<td>Dana C Nguyen BSN, RN, CIC</td>
<td>Updated to reflect current standards and modes of naloxone available for dispensing.</td>
</tr>
</tbody>
</table>